EcoDrugPlus

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSOMEG00000019478
Gene Symbol: SCN8A
2 Cross references
215 Possible Orthologues:

Sodium/glucose Cotransporter 1-Like

Ensembl ID : ENSOMEG00000001665
Gene Symbol: LOC112163426
3 Cross references
247 Possible Orthologues:

Sodium/hydrogen Exchanger 3-Like

Ensembl ID : ENSOMEG00000022221
Gene Symbol: LOC112160835
3 Cross references
234 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Alpha-1

Ensembl ID : ENSOMEG00000014415
Gene Symbol: LOC112156656
2 Cross references
181 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Beta-2-Like

Ensembl ID : ENSOMEG00000003085
Gene Symbol: LOC112142741
3 Cross references
203 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Beta-233-Like

Ensembl ID : ENSOMEG00000010442
Gene Symbol: LOC112142014
3 Cross references
220 Possible Orthologues:

Solute Carrier Family 10 Member 2

Ensembl ID : ENSOMEG00000017942
Gene Symbol: SLC10A2
3 Cross references
214 Possible Orthologues:

Solute Carrier Family 18 Member A2

Ensembl ID : ENSOMEG00000001173
Gene Symbol: SLC18A2
3 Cross references
216 Possible Orthologues:

Solute Carrier Family 22 Member 6-Like

Ensembl ID : ENSOMEG00000020052
Gene Symbol: LOC112143061
3 Cross references
358 Possible Orthologues:

Solute Carrier Family 29 Member 1 (Augustine Blood Group)

Ensembl ID : ENSOMEG00000007755
Gene Symbol: SLC29A1
3 Cross references
210 Possible Orthologues:

Solute Carrier Family 5 Member 1

Ensembl ID : ENSOMEG00000001640
Gene Symbol: SLC5A1
1 Cross references
247 Possible Orthologues:

Solute Carrier Family 5 Member 2

Ensembl ID : ENSOMEG00000018418
Gene Symbol: SLC5A2
1 Cross references
198 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).